Previous 10 | Next 10 |
2024-01-18 09:12:34 ET Summary Shares of Tourmaline Bio, Inc. have surged 200% since its public debut in October 2023. The company's main asset, TOUR006, shows potential as a therapy for thyroid eye disease and atherosclerotic cardiovascular disease. Tourmaline is conducting P...
2024-01-17 04:20:00 ET Summary The beginning of every month is exciting for all dividend income investors as we look back at the previous month and see how much passive dividend income our portfolios generated. Looking back at my December totals, I see that my year-over-year progr...
2024-01-16 10:50:09 ET Summary Investors are monitoring the S&P 500 stocks as the index starts the year with a pullback and uncertainty over interest rate cuts. Top-performing stocks include Juniper, Nvidia, Eli Lilly, Viatris, and Organon, while solar energy stocks and Boeing...
2024-01-14 08:45:13 ET Summary Verve Therapeutics aims to revolutionize treatment for cardiovascular disease through in vivo gene therapy using base editing technology. Their lead candidate, VERVE-101, has shown promising results in reducing LDL-C levels in preclinical studies. ...
2024-01-12 12:19:52 ET Summary My dividend growth portfolio has consistently grown income in excess of 10% annually. However, the risks of dividend cuts are building. A review of the portfolio's positions and sector weighting and discuss how they have changed over time. I disc...
2024-01-12 06:52:07 ET Summary Hertz's decision to sell off its electric vehicle fleet contributes to a decline in share prices for EV companies like Tesla, Rivian, and Fisker. Toyota's stock rises while other automakers, including Ford and General Motors, see negative territory. ...
2024-01-11 15:37:25 ET Cytokinetics: Clear Win For Aficamten In SEQUOIA-HCM Phase 3 Trial (Upgrade) Cytokinetics: Buyout Rumors Ahead Of The Key Phase 3 Readout Of Aficamten Cytokinetics, Incorporated (CYTK) Q3 2023 Earnings Call Transcript Cytokinetics plunges a...
2024-01-10 17:52:32 ET Summary Warren Buffett said that passive income snowballs are the key to financial independence. ETFs can be a great vehicle for building a passive income snowball. We compare two popular dividend ETFs and share our take on which one makes for a better p...
2024-01-10 08:30:36 ET NetworkNewsWire Editorial Coverage New York, NY – January 10, 2024 – On Sept. 20, 2019, history was made when the U.S. Food and Drug Administration approved Rybelsus as the first oral glucagon-like peptide-1 (GLP-1) agonist for type 2 dia...
2024-01-10 08:20:42 ET More on Amgen Amgen Inc. (AMGN) Presents at J.P. Morgan 42nd Annual Healthcare Conference 2024 (Transcript) Amgen: Wonderful Stock At Decent Price Amgen: Bet On Its Breakthrough Drug Pharma and biotech deal values spike 35% in 2023: rep...
News, Short Squeeze, Breakout and More Instantly...
2024-07-18 10:30:00 ET Stock Traders Daily has produced this trading report using a proprietary method. This methodology seeks to optimize the entry and exit levels to maximize results and limit risk, and it is also applied to Index options, ETFs, and futures for our subscribers. This...
2024-07-15 07:58:00 ET Can a biotechnology company pay a generous dividend in 2024? The answer is definitely yes, as Amgen (NASDAQ: AMGN) is evidently unafraid to reward its loyal shareholders with quarterly cash payments. Just as importantly, Amgen is a recent revenue growe...
2024-07-14 06:30:00 ET Income investors don't have to settle for dividends that tread water. There are plenty of stocks to buy that offer growing dividends and are poised to keep the momentum going along with attractive dividend yields . Three Motley Fool contributors think they've ...